Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IN10018 plus pegylated liposomal doxorubicin versus placebo plus pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer
CTR20221614Phase 3Active
- Sponsor
- InnoCare Pharma
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ifebemtinib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by InnoCare Pharma. Started Sep 2022; status: active.
02
Drugs
ifebemtinib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20221614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221614.